Actively Recruiting
Using FAPI PETMRI Scans to Improve Diagnosis and Monitoring of Prostate Cancer in Adults
Led by University of Wisconsin, Madison · Updated on 2026-06-10
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how a fibroblast activation protein inhibitor FAPI binds to certain cells in prostate cancer tumors to improve diagnosis and monitoring of this disease. This Phase 2 clinical trial focuses on patients with prostate cancer or those at high risk for metastatic prostate cancer. The study aims to understand how FAPI PETMRI imaging can help detect and track prostate cancer lesions more accurately. Participants will receive an injection of approximately 5 mCi of Ga-FAPI-46, which is a radioactive tracer used during PET scans. They will undergo two combined PETMRI scans across two separate research visits, with each visit lasting up to 2.5 hours. The FAPI tracer highlights cancer cells during imaging, allowing detailed assessment of tumor tissue. During the study, participants will have two imaging sessions to evaluate how well FAPI detects lesions, how much the tracer is taken up by tumors, and changes in tumor volume. The scans last up to 80 minutes each. Researchers will monitor these imaging results to better understand FAPIs diagnostic performance. The study spans from February 2026 to January 2027, with no treatment involved beyond the imaging procedures.
CONDITIONS
Brief Title
Using FAPI PET/MRI to Evaluate Prostate Cancer
Research Team
R
Radiology Studies
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here